Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lyell Immunopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Lyell Immunopharma, Inc.’s stock price such as:

• Lyell Immunopharma, Inc.’s current stock price and volume
• Why Lyell Immunopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for LYEL from analysts
• LYEL’s stock price momentum as measured by its relative strength

About Lyell Immunopharma, Inc. (LYEL)

Before we jump into Lyell Immunopharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Want to learn more about Lyell Immunopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:15 PM, CST, Lyell Immunopharma, Inc.’s stock price was $9.830.

Lyell Immunopharma, Inc. is down 8.98% from its previous closing price of $10.800.

During the last market session, Lyell Immunopharma, Inc.’s stock traded between $9.700 and $10.830. Currently, there are approximately 14.75 million shares outstanding for Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lyell Immunopharma, Inc. Stock Price History

Lyell Immunopharma, Inc.’s (LYEL) price is currently up 12.55% so far this month.

During the month of June, Lyell Immunopharma, Inc.’s stock price has reached a high of $13.800 and a low of $7.650.

Over the last year, Lyell Immunopharma, Inc. has hit prices as high as $53.500 and as low as $7.650. Year to date, Lyell Immunopharma, Inc.’s stock is down 23.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lyell Immunopharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were analysts who downgraded Lyell Immunopharma, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lyell Immunopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lyell Immunopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lyell Immunopharma, Inc. (LYEL) by visiting AAII Stock Evaluator.

Relative Price Strength of Lyell Immunopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Lyell Immunopharma, Inc. has a weighted four-quarter relative price strength of -30.60%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how Lyell Immunopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lyell Immunopharma, Inc. Stock Price: Bottom Line

As of June 11, 2025, Lyell Immunopharma, Inc.’s stock price is $9.830, which is down 8.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lyell Immunopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.